Eupraxia Pharmaceuticals Announces Quarterly Earnings Results

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has released its earnings results for the most recent quarter, announcing a loss of ($0.21) in earnings per share (EPS), as reported by Zacks.

Eupraxia Pharmaceuticals Stock Performance

On Thursday, Eupraxia Pharmaceuticals' stock experienced a decline of $0.11, settling at a price of $3.91 during midday trading. A total of 5,147 shares changed hands, which is lower than the average trading volume of 16,544 shares. The company's market capitalization stands at $139.38 million, and it has a price-to-earnings (PE) ratio of -5.43. Currently, the stock's fifty-day moving average is $3.46, while the two-hundred-day moving average is $3.09. Eupraxia Pharmaceuticals' shares have witnessed a twelve-month low of $2.20 and a high of $4.48.

Wall Street Analyst Insights

In related news, Craig Hallum initiated coverage on Eupraxia Pharmaceuticals, issuing a research report on February 21st. They have assigned a "buy" rating to the stock along with a target price set at $12.00.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology firm dedicated to the development of locally delivered, extended-release products. These products are designed to meet significant unmet medical needs. The company’s lead product candidate is EP-104IAR, which is being developed to treat pain associated with osteoarthritis of the knee.

Investment Considerations

Before considering an investment in Eupraxia Pharmaceuticals, it is advisable to review the current market insights. Although Eupraxia Pharmaceuticals is rated as a Strong Buy by some analysts, there are other stocks that top-rated analysts believe could offer better investment opportunities.

Investors are encouraged to analyze market conditions carefully, especially in times of uncertainty. Using various strategies to protect your investment portfolio may be beneficial.

Earnings, Stocks, Pharmaceuticals